SUMMARY OF BASIC LEASE INFORMATIONLease • July 5th, 2019 • RAPT Therapeutics, Inc. • Pharmaceutical preparations • California
FLX BIO, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • July 5th, 2019 • RAPT Therapeutics, Inc. • Pharmaceutical preparations • California
This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 18th day of December, 2018, by and among FLX Bio, Inc., a Delaware corporation (the “Company”), and the investors listed on Schedule A hereto, each of which is herein referred to as an “Investor” and collectively as the “Investors” and amends and restates in its entirety the Prior Agreement (as defined below).
FIRST AMENDMENT TO LEASELease • July 5th, 2019 • RAPT Therapeutics, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO LEASE (“Amendment”) is made and entered into as of April 29, 2015, by and between HCP, INC., a Delaware corporation (“Landlord”), and FLX BIO, INC., a Delaware corporation (“Tenant”).
THIRD AMENDMENT TO LEASELease • July 5th, 2019 • RAPT Therapeutics, Inc. • Pharmaceutical preparations
This THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made and entered into as of December 13, 2018 (the “Effective Date”), by and between HCP, INC., a Delaware corporation (“Landlord”), and FLX BIO, INC., a Delaware corporation (“Tenant”).
SECOND AMENDMENT TO LEASELease • July 5th, 2019 • RAPT Therapeutics, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO LEASE (this “Second Amendment”) is made and entered into as of April 16, 2018 (the “Effective Date”), by and between HCP, INC., a Delaware corporation (“Landlord”), and FLX BIO, INC., a Delaware corporation (“Tenant”).
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT by and between MSD International GmbH and FLX Bio, Inc. Dated: November 1, 2018Clinical Trial Collaboration and Supply Agreement • July 5th, 2019 • RAPT Therapeutics, Inc. • Pharmaceutical preparations • New York
This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), is entered into as of November 1, 2018 (the “Effective Date”), by and between MSD International GmbH, having a place of business at Weystrasse 20, 6000 Luzern 6, Switzerland (“Merck”), and FLX Bio, Inc., having a place of business at 561 Eccles Ave., South San Francisco, CA 94080 (“FLX”). Merck and FLX are each referred to herein individually as “Party” and collectively as “Parties”.
